TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是通过比较研究中随机给予辛伐他汀的受试者与研究中给予安慰剂的受试者，评估辛伐他汀减缓阿尔茨海默病进展的安全性和有效性。 辛伐他汀是FDA批准的处方口服药物，用于降低血液中的胆固醇水平，降低心脏病发作，中风和死亡的风险。 这是一项由美国国立卫生研究院赞助的试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the safety and efficiency of Simvastatin to slow the progression of Alzheimer's by comparing subjects in the study who are randomly given Simvastatin with those also in the study who are instead given placebo. Simvastatin is a FDA approved prescription oral medication used to lower cholesterol levels in the blood and reduces the risk of heart attack, stroke, and death. This is an NIH sponsored trial.